Home / Health / FDA Panel Rejects AstraZeneca Breast Cancer Drug
FDA Panel Rejects AstraZeneca Breast Cancer Drug
1 May
Summary
- Outside FDA experts voted against AstraZeneca's breast cancer drug.
- The drug, camizestrant, targets a specific cancer mutation.
- The panel voted 3 to 6 against the drug's risk-benefit profile.
An independent panel advising the U.S. Food and Drug Administration has voted against the approval of AstraZeneca's experimental breast cancer medication, camizestrant. The Oncologic Drugs Advisory Committee, comprised of external experts, cast a 3-to-6 vote, signaling concerns about the drug's overall risk-benefit assessment.
Camizestrant is under development as a potential first-line therapy for a subtype of breast cancer. This specific cancer type is identified by the presence of a particular genetic mutation within the tumor cells. The panel's decision represents a significant hurdle for the drug's path to market.
Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.
